Patents by Inventor Eduardo Setti

Eduardo Setti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS
    Publication number: 20130296363
    Abstract: Provided herein are compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: November 7, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Raffaella Faraoni, Michael J. Hadd, Mark W. Holladay, Martin W. Rowbottom, Eduardo Setti
  • JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130245014
    Abstract: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: October 4, 2012
    Publication date: September 19, 2013
    Applicant: Ambit Biosciences Corp.
    Inventors: Sunny Abraham, Qi Chao, Michael J. Hadd, Mark W. Holladay, Liu Gang, Eduardo Setti
  • JAK kinase modulating compounds and methods of use thereof
    Patent number: 8349851
    Abstract: Provided herein are quinazoline compounds of formula (I): The compounds are useful for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: January 8, 2013
    Assignee: Ambit Biosciences Corp.
    Inventors: Sunny Abraham, Qi Chao, Michael J. Hadd, Mark W. Holladay, Gang Liu, Eduardo Setti
  • OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20120053194
    Abstract: Provided herein is an optically active pyrozolylaminoquinazaline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a proliferative disease, inflammatory disease, or renal disease.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 1, 2012
    Applicant: Ambit Biosciences Corp.
    Inventors: Mark W. Holladay, Eduardo Setti
  • OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20120053193
    Abstract: Provided herein is an optically active pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. Further provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a proliferative disease, inflammatory disease, or renal disease.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 1, 2012
    Applicant: AMBIT BIOSCIENCES CORP.
    Inventors: Mark W. Holladay, Eduardo Setti
  • JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20110269740
    Abstract: Provided herein are pyrrolotriazine compounds for treatment of JAK kinase, including JAK2 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: July 2, 2009
    Publication date: November 3, 2011
    Inventors: Sunny Abraham, Qi Chao, Michael Hadd, Mark Holladay, Gang Liu, Mitchell Nambu, Eduardo Setti
  • RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20110118245
    Abstract: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.
    Type: Application
    Filed: March 17, 2009
    Publication date: May 19, 2011
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20100317659
    Abstract: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: February 26, 2010
    Publication date: December 16, 2010
    Inventors: Sunny Abraham, Qi Chao, Michael J. Hadd, Mark W. Holladay, Gang Liu, Eduardo Setti
  • Novel hydroxamates as therapeutic agents
    Publication number: 20050227976
    Abstract: The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Application
    Filed: April 7, 2005
    Publication date: October 13, 2005
    Applicant: AXYS PHARMACEUTICALS, INC.
    Inventor: Eduardo Setti
  • Cyanoalkylamino derivatives as protease inhibitors
    Publication number: 20050014941
    Abstract: The present invention is directed to novel cyanoalkylamino derivatives that are inhibitors of cysteine protease such as cathepsins K, S, B and L, in particular cathepsin K Pharmaceutical composition comprising these compounds, method of treating diseases mediated by unregulated cysteine protease activity, in particular cathepsin K utilizing these compounds and methods of preparing these compounds are also disclosed.
    Type: Application
    Filed: November 13, 2002
    Publication date: January 20, 2005
    Inventors: Cameron Black, Sheldon Crane, Dana Davis, Eduardo Setti
  • Compounds and compositions as protease inhibitors
    Patent number: 6525036
    Abstract: The present invention relates to novel cysteine protease inhibitors of Formula I: the pharmaceutically acceptable salts and N-oxide derivatives thereof, their use as therapeutic agents and methods of making them.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: February 25, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Renata Marcella Oballa, Petpiboon Prasit, Joel Stephane Robichaud, Elise Isabel, Eduardo Setti, Dan-Xiong Wang, Rohan V. Mendonca, Shankar Venkatraman
  • Novel compounds and compositions as protease inhibitors
    Publication number: 20020052378
    Abstract: The present invention relates to novel cysteine protease inhibitors of Formula I: 1
    Type: Application
    Filed: January 5, 2001
    Publication date: May 2, 2002
    Inventors: Renata Marcella Oballa, Petpiboon Prasit, Joel Stephane Robichaud, Elise Isabel, Eduardo Setti, Dan-Xiong Wang, Rohan V. Mendonca, Shankar Venkatraman